medicina61巻3号

2024年03月発行

特集 どこでもみれる?—コモンディジーズとしての感染症アップデート ワクチンアップデート

肺炎球菌ワクチン—PPSV23，PCV13の効果の違いと使い分け

著者： 三村一行¹

所属機関： ¹埼玉医科大学総合医療センター総合診療内科

ページ範囲：P.535 - P.539

Point
◎肺炎球菌莢膜多糖体ワクチン（PPSV）は単独接種ではワクチン含有血清型の侵襲性肺炎球菌感染症（IPD）にのみワクチン効果を認めるが，インフルエンザワクチンと併用することでIPD以外の肺炎球菌感染症にも予防効果が得られる．
◎肺炎球菌結合型ワクチン（PCV）は単独接種においてIPD以外にも菌血症を伴わない肺炎球菌性肺炎や免疫機能低下例についても有効性を示し，集団免疫効果も期待できるワクチンである．
◎近年，非ワクチン含有血清型による肺炎球菌感染症の増加（血清型置換）が問題となっている．
◎連続接種に関しては，初回にPCVを接種し，その1年後を目安にPPSV接種を行うと免疫原性が高まり，より高い臨床効果が得られる．

参考文献

1）van der Poll T, Opal SM：Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374：1543-1556, 2009 PMID 19880020

by polymerase chain reaction. J Infect Chemother 3：190-197, 1997 PMID 29681341

における抗菌薬感受性およびpenicillin-binding-protein遺伝子変異の変動．日化療会誌64：76-81, 2016

4）Black S, et al：Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24（Suppl 2）：S2-79-80, 2006 PMID 16823937

5）Pollard AJ, et al：Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9：213-220, 2009 PMID 19214194

6）Rappuoli R, et al：On the mechanisms of conjugate vaccines. Proc Natl Acad Sci USA 116：14-16, 2019 PMID 30578318

7）Noguchi S, et al：Distribution and annual changes in the proportion of Streptococcus pneumoniae serotypes in Japanese adults with pneumococcal pneumonia from 2011 to 2017. J Infect Chemother 25：925-929, 2019 PMID 31350184

8）Shimbashi R, et al：Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal diseases in adults, Japan, 2013-2017. Emerg Infect Dis 26：2378-2386, 2020 PMID 32946721

9）Suzuki M, et al：Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older；A multicentre, prospective, test-negative design study. Lancet Infect Dis 17：313-321, 2017 PMID 28126327

10）Moberley S, et al：Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013：CD000422, 2013 PMID 24388246

11）Maruyama T, et al：Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing pneumonia and improving survival in nursing home residents；Double blind, randomized and placebo controlled trial. BMJ 340：c1004, 2010 PMID 20211953

12）Kawakami K, et al：Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28：7063-7069, 2010 PMID 20723631

13）Christenson B, et al：Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 23：363-368, 2004 PMID 15065822

14）Hung IF, et al：Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination；A prospective cohort study. Clin Infect Dis 51：1007-1016, 2010 PMID 20887208

15）Bonten MJ, et al：Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372：1114-1125, 2015 PMID 25785969

16）Platt HL, et al：A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older（PNEU-AGE）. Vaccine 40：162-172, 2022 PMID 34507861

17）French N, et al：A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362：812-822, 2010 PMID 20200385

18）Griffin MR, et al：U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 369：155-163, 2013 PMID 23841730

19）Waight PA, et al：Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction；An observational cohort study. Lancet Infect Dis 15：535-543, 2015 PMID 25801458

20）Centers for Disease Control and Prevention：Pneumococcal Disease. Surveillance and Reporting.　https://www.cdc.gov/pneumococcal/surveillance.html（2023年12月閲覧）

21）Jackson LA, et al：Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 31：3585-3593, 2013 PMID 23688527

22）Jackson LA, et al：Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31：3594-3602, 2013 PMID 23688525

23）Greenberg RN, et al：Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 32：2364-2374, 2014 PMID 24606865

24）Pollard AJ, et al：Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9：213-220, 2009 PMID 19214194

25）Jackson LA, et al：Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine naive adults. Vaccine 31：3577-3584, 2013 PMID 23688526

26）Azuma M, et al：Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years；Comparison of booster effects based on intervals of 0.5 and 1.0 year. Vaccine 41：1042-1049, 2023 PMID 36593171

27）Song J-Y, et al：Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≧ 50 years；A randomized phase Ⅲ trial（PNEU-PATH）. Vaccine 39：6422-6436, 2021 PMID 34489128

28）Heo JY, et al：Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults；A prospective, test-negative study. J Infect Dis 225：836-845, 2022 PMID 34537847

29）Kobayashi M, et al：Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults；Updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep 71：109-117, 2022 PMID 35085226

30）Centers for Disease Control and Prevention：Pneumococcal Vaccine Timing for Adults.　https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf（2023年12月閲覧）

31）日本呼吸器学会・日本感染症学会・日本ワクチン学会合同委員会：65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第4版2023年3月24日）　https://www.kansensho.or.jp/modules/guidelines/index.php?content_id=51#06（2023年12月閲覧）